Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Fabre

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Plos One|July 15, 2016
Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity ConsiderationsEleonora Zonta, Fanny Garlan, Nicolas Pécuchet, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2012
Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 studyStéphane Oudard, Rokhaya Thiam, Laure S Fournier, et al.
Cancers|August 4, 2017
Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung CancerAntoine Legras, Nicolas Pécuchet, Sandrine Imbeaud, et al.
Plos Medicine|December 28, 2016
Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective StudyNicolas Pécuchet, Eleonora Zonta, Audrey Didelot, et al.
Clinical Chemistry|September 15, 2016
Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNANicolas Pécuchet, Yves Rozenholc, Eleonora Zonta, et al.
Cancers|December 9, 2023
Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond ProgressionIvan Pourmir, Reza Elaidi, Zineb Maaradji, et al.
Lung Cancer (Amsterdam, Netherlands)|April 2, 2021
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie studyNicolas Epaillard, Jose Carlos Benitez, Teresa Gorria, et al.
Breast Cancer Research : BCR|December 6, 2008
PAI-1 and functional blockade of SNAI1 in breast cancer cell migrationElizabeth Fabre-Guillevin, Michel Malo, Amandine Cartier-Michaud, et al.
Journal of Translational Medicine|May 15, 2023
A novel Chr1-miR-200 driven whole transcriptome signature shapes tumor immune microenvironment and predicts relapse in early-stage lung adenocarcinomaSimon Garinet, Audrey Didelot, Laetitia Marisa, et al.
Cancer Treatment Reviews|March 17, 2018
Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and cliniciansSophie Outh-Gauer, Marie Alt, Christophe Le Tourneau, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Plos One|July 15, 2016
Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity ConsiderationsEleonora Zonta, Fanny Garlan, Nicolas Pécuchet, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2012
Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 studyStéphane Oudard, Rokhaya Thiam, Laure S Fournier, et al.
Cancers|August 4, 2017
Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung CancerAntoine Legras, Nicolas Pécuchet, Sandrine Imbeaud, et al.
Plos Medicine|December 28, 2016
Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective StudyNicolas Pécuchet, Eleonora Zonta, Audrey Didelot, et al.
Clinical Chemistry|September 15, 2016
Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNANicolas Pécuchet, Yves Rozenholc, Eleonora Zonta, et al.
Cancers|December 9, 2023
Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond ProgressionIvan Pourmir, Reza Elaidi, Zineb Maaradji, et al.
Lung Cancer (Amsterdam, Netherlands)|April 2, 2021
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie studyNicolas Epaillard, Jose Carlos Benitez, Teresa Gorria, et al.
Breast Cancer Research : BCR|December 6, 2008
PAI-1 and functional blockade of SNAI1 in breast cancer cell migrationElizabeth Fabre-Guillevin, Michel Malo, Amandine Cartier-Michaud, et al.
Journal of Translational Medicine|May 15, 2023
A novel Chr1-miR-200 driven whole transcriptome signature shapes tumor immune microenvironment and predicts relapse in early-stage lung adenocarcinomaSimon Garinet, Audrey Didelot, Laetitia Marisa, et al.
Cancer Treatment Reviews|March 17, 2018
Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and cliniciansSophie Outh-Gauer, Marie Alt, Christophe Le Tourneau, et al.
Pageof 8